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Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease affecting the motor system.
Although the etiology of the disease is not fully understood, microglial activation and neuroinflammation are
thought to play a role in disease progression.
Methods: We examined the immunohistochemical expression of two markers of microglial phenotype, the
arginine-metabolizing enzymes inducible nitric oxide synthase (iNOS) and arginase1 (Arg1), in the spinal cord of a
mouse model carrying an ALS-linked mutant human superoxide dismutase transgene (SOD1G93A) and in non-
transgenic wild-type (WT) mice. Immunolabeling for iNOS and Arg1 was evaluated throughout disease progression
(6 to 25 weeks), and correlated with body weight, stride pattern, wire hang duration and ubiquitin pathology. For
microglia and motor neuron counts at each time point, SOD1G93A and WT animals were compared using an
independent samples t-test. A Welch t-test correction was applied if Levene’s test showed that the variance in WT
and SOD1G93A measurements was substantially different.
Results: Disease onset, measured as the earliest change in functional parameters compared to non-transgenic WT
mice, occurred at 14 weeks of age in SOD1G93A mice. The ventral horn of the SOD1G93A spinal cord contained more
microglia than WT from 14 weeks onwards. In SOD1G93A mice, Arg1-positive and iNOS-positive microglia increased
18-fold and 7-fold, respectively, between 10 and 25 weeks of age (endpoint) in the lumbar spinal cord, while no
increase was observed in WT mice. An increasing trend of Arg1- and iNOS-expressing microglia was observed in
the cervical spinal cords of SOD1G93A mice. Additionally, Arg1-negative motor neurons appeared to selectively
decline in the spinal cord of SOD1G93A mice, suggesting that Arg1 may have a neuroprotective function.
Conclusions: This study suggests that the increase in spinal cord microglia occurs around and after disease onset
and is preceded by cellular pathology. The results show that Arg1 and iNOS, thought to have opposing
inflammatory properties, are upregulated in microglia during disease progression and that Arg1 in motor neurons
may confer protection from disease processes. Further understanding of the neuroinflammatory response, and the
Arg1/iNOS balance in motor neurons, may provide suitable therapeutic targets for ALS.
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Amyotrophic lateral sclerosis (ALS) is a progressive neuro-
degenerative disease affecting the motor system. In ALS,
spinal cord motor neurons degenerate and die, causing
progressive paresis and paralysis leading to death due to re-
spiratory failure within 2 to 5 years of diagnosis. Disease
etiology is not fully understood, and there is only one
therapeutic (Riluzole) shown to extend ALS patient life-
span for a matter of months [1]. It is therefore important
to characterize the processes involved in disease progres-
sion in order to identify potential new therapeutic targets.
A key discovery was the identification of mutations in the
antioxidant enzyme Cu/Zn superoxide dismutase 1 (SOD1)
gene as the cause of approximately 20% of familial ALS [2].
SOD1 mutations lead to a toxic gain of function, triggering
a cascade of events that lead to the degeneration of motor
neurons [3]. Expression of a mutant human SOD1 trans-
gene in mice (SOD1G93A mice) results in similar pathology
and symptoms to human ALS [4]; SOD1G93A mice are cur-
rently the most widely used ALS mouse model.
Although ALS is characterized primarily by selective de-
generation of motor neurons, it is increasingly regarded as
a complex multifactorial disease involving dysregulation of
cellular processes affecting both neurons and glial cells
[5-7]. Two proposed pathogenic mechanisms in ALS are
oxidative stress and neuroinflammation. Biochemical
markers of oxidative injury are increased in tissue speci-
mens from ALS patients, while SOD1G93A mice show ele-
vated levels of protein oxidation and nitrosylation, and
lipid oxidation [8,9]. Microglial activation is apparent in
tissue from ALS patients [10], and is also readily apparent
in SOD1G93A mice [11], with a switch from the neuropro-
tective M2-like microglial phenotype to the neurotoxic
M1-like microglial phenotype associated with the transi-
tion of SOD1G93A mice from a stable to a rapidly progres-
sive phase of disease [12,13].
The metabolism of nitric oxide (NO) may provide a link
between microglial activation and oxidative injury to
motor neurons: microglial-mediated damage to motor
neurons in cell culture is partially dependent on the pro-
duction of microglial NO [14]. The mutant SOD1 may
have the capacity to catalyze the production of reactive
oxygen species such as peroxynitrite [15], also contributed
to by increased cellular expression of inducible nitric
oxide synthase (iNOS) [16]. In microglia, the production
of NO is regulated by the relative amounts of two
arginine-metabolizing enzymes, arginase 1 (Arg1) and in-
ducible nitric oxide synthase (iNOS) - Arg1 converts ar-
ginine into ornithine and urea, while iNOS converts
arginine into citrulline and produces NO [17]. iNOS pro-
tein expression in SOD1G93A mice has been reported in
glial cells especially in the ventral horn [18], while immu-
noreactivity for Arg1 has been demonstrated in motor
neurons in SOD1G93A and non-transgenic mice [19]. Asmicroglial expression of Arg1 and iNOS varies with M1
and M2 microglial phenotypes [20], the production of NO
may play an important role in the putative M2-to-M1
switch and subsequent toxicity to motor neurons [13].
Whilst iNOS and Arg1 act on the same substrate but lead
to opposing outcomes [17], they have not been investi-
gated in microglia and motor neurons in the same experi-
mental preparation.
In this study we characterized changes in lumbar and
cervical spinal cord microglia in terms of Arg1 and iNOS
protein expression, from pre-symptomatic to end-stage in
the SOD1G93A mice. We have temporally compared
microglial changes with the onset of functional deficits,
and with the appearance of spinal cord ubiquitin path-
ology in these mice. Additionally, we have examined ex-
pression of Arg1 in lumbar motor neurons. Our findings
demonstrate increasing expression of Arg1 and iNOS pro-




All procedures involving animals were approved by the
University of Tasmania Animal Ethics Committee (permit
numbers A10995 and A11958) and were consistent with
the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes. SOD1G93A mice with ad-
vanced symptoms of ALS had food placed on bedding, to
ensure easy access and continued nutrition. All perfusions
were carried out under terminal sodium pentobarbitone
anesthesia when all reflexes were absent.
Animals
SOD1G93A transgenic mice (B6.Cg-Tg(SOD1*G93A)
1Gur/J, Jackson Laboratories, Bar Harbor, ME, USA)
and wild-type littermates (WT; C57BL/6) were main-
tained in a 12 hour light: dark cycle in filtered, sterile air
by the University of Tasmania Animal Services. All mice
were housed in OptiMICE cages with standard bedding,
and were provided with food and water ad libitum. Pres-
ence of the SOD1G93A transgene was assessed according
to standard protocols [21].
Reagents
Nitric acid, sodium azide, paraformaldehyde, urea, citric
acid and sodium citrate were obtained from Fluka and
Sigma (Sigma-Aldrich, St Louis, MO, USA). Biotinylated
tomato lectin (TL), normal goat serum, the Mouse on
Mouse (MOM) reagent kit, and the streptavidin/biotin
blocking kit were obtained from Vector Laboratories
(Burlingame, CA, USA). The following primary anti-
bodies were used: anti-ionized calcium binding adaptor
molecule 1 (Iba1, Wako, Osaka, Japan); anti-iNOS
(Santa Cruz Biotechnology, Dallas, TX, USA); anti-Arg1
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Carpinteria, CA, USA); and anti-dephosphorylated neu-
rofilament heavy and medium chain (SMI32, Covance,
Princeton, NJ, USA) (Table 1). AlexaFluor-conjugated
and biotin-conjugated secondary antibodies, AlexaFluor-
conjugated streptavidin, and Nuclear Yellow dye were
obtained from Molecular Probes (Life Technologies,
Carlsbad, CA, USA) (Table 1).
Preparation of time-series spinal cord tissue from SOD1G93A
and wild-type mice
Time points
Spinal cord samples were obtained from SOD1G93A mice
and their WT littermates at 6, 10, 14, 18 and 22 weeks of
age, and at disease endpoint. Disease endpoint, measured
as a 20% reduction from pre-disease maximum body
weight, typically occurred at 25 weeks of age in SOD1G93A
mice, with WT mice at 25 weeks of age used for compari-
son. For each of the above time points, lumbar spinal cord
samples were obtained from three animals per genotype
per time point (a mixture of male and female mice), with
the exception of two WT mice at 6 weeks of age, and at
22 weeks of age when four animals per genotype were used.
For an additional comparison, cervical spinal cord was ob-
tained from two animals per genotype at 10 weeks of age,
three WT and two SOD1G93A mice at 14 weeks of age, and
three animals per genotype at 18 and 22 weeks of age.
Perfusion and tissue preparation
At the appropriate time point, animals were deeply anes-
thetized with sodium pentobarbitone (60 mg/kg, intra-
peritoneally). When all reflexes were absent, mice were
transcardially perfused with 10 mL 10 mM PBS followed
by 20 mL 4% w/v paraformaldehyde (PFA) in PBS. The
T12-L1 vertebrae, containing the L2-L5 lumbar spinal






Anti-dephosphorylated neurofilament (SMI32) Mouse mo
*Anti-rabbit IgG, biotinylated Goat polyc
*Anti-rabbit IgG, AlexaFluor®594-conjugated Goat polyc
*Anti-mouse IgG, AlexaFluor®488-conjugated Goat polyc
*MOM kit anti-mouse IgG, biotinylated MOM kit
Streptavidin, AlexaFluor®488-conjugated Streptavidi
Streptavidin, AlexaFluor®594-conjugated Streptavidi
Nuclear yellow Nuclear dy
*Secondary antibodies. Iba1, ionized calcium binding adaptor molecule 1; iNOS, inducibleovernight at 4°C, then stored in PBS with 0.01% w/v so-
dium azide. Cervical vertebrae, from the subset of ani-
mals described above, were collected in the same
manner. All samples were incubated in rapid decalcifica-
tion solution (5% v/v nitric acid with 0.05% w/v urea) for
2 hours at room temperature, then washed thoroughly
with distilled water. Decalcified samples were dehy-
drated and embedded in paraffin wax using an auto-
mated tissue processor (Leica Biosystems ASP200-S,
Melbourne, Australia). Sections (4 μm) were cut on a
microtome (Microm HM325, Walldorf, Germany),
mounted on Flex slides (Dako), dried at 37°C overnight
and then stored at room temperature. Prior to immu-
nohistochemistry, paraffin-embedded sections were
heated to 60°C for 10 minutes for efficient paraffin re-
moval, dewaxed in xylene and rehydrated through a
series of graded ethanols to distilled water.
Immunolabeling for microglial markers, inducible nitric
oxide synthase and arginase1 in paraffin-embedded
SOD1G93A and wild-type spinal cord tissue
Spinal cord microglia were identified either by anti-Iba1
immunolabeling or by TL labeling [22,23]. TL labeling
was also observed in some endothelial cells and motor
neurons, which could be distinguished from microglia by
their different size and morphology. iNOS and Arg1 are
considered putative M1 and M2 microglial markers, re-
spectively [20]. Immunostaining for Iba1 and for Arg1 was
preceded by antigen retrieval. Antigen retrieval was per-
formed by heating slides in 10 mM citrate buffer, pH 6
(2 mM citric acid, 8 mM sodium citrate) in a pressure
cooker (Russell Hobbs, Braeside, Australia) at 100% power
for 6 minutes followed by 60% power for 14 minutes, then
cooled to room temperature and rinsed in PBS.
All immunostaining steps were carried out in a hu-
midified light-safe chamber at room temperature unlesshemistry
Dilution Incubation
yclonal 1:500 2 hours, RT
noclonal 1:100 2 hours, RT
noclonal 1:100 O/N, 4°C
yclonal 1:1000 O/N, RT
noclonal 1:2000 O/N, RT
lonal 1:500 1 hour, RT
lonal 1:1000 2 hours, RT
lonal 1:1000 2 hours, RT
1:250 20 minutes, RT
n 1:500 1 hour, RT
n 1:500 2 hours, RT
e 1:10000 20 minutes, RT
nitric oxide synthase; O/N, overnight; MOM, Mouse on Mouse; RT, room temperature.
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PBS between steps. To detect Iba1, sections were blocked
with 10% v/v normal goat serum in PBS for 1 hour, then in-
cubated with anti-Iba1, biotinylated goat anti-rabbit sec-
ondary antibody, streptavidin-AlexaFluor488 and Nuclear
Yellow in PBS (Table 1). To detect Arg1 and iNOS, the
MOM kit was used according to the manufacturer’s in-
structions. Briefly, sections were blocked with MOM block-
ing reagent for 1 hour and rinsed with PBS and MOM
diluent; primary antibody (Arg1 or iNOS) was applied in
MOM diluent, then detected with MOM biotinylated sec-
ondary antibody and streptavidin-AlexaFluor488 (Table 1).
Following Arg1 or iNOS labeling, any free binding sites
were blocked using the streptavidin/biotin blocking kit ac-
cording to the manufacturer’s instructions; sections were
then incubated with biotinylated TL (1:500, 1 hour),
streptavidin-AlexaFluor594, and Nuclear Yellow (Table 1).
All slides were coverslipped with aqueous fluorescence
mounting medium (Dako).
Microglial image analysis and cell counts
Images were captured with an Olympus BX50 fluorescence
microscope fitted with a CoolSnapHQ2 camera (Photo-
metrics, Tucson, AZ, USA). Immunohistochemistry counts
for Iba1-, TL-, Arg1- and iNOS-positive cells were per-
formed on three cross sections from the lumbar spinal
cord, each separated by a minimum distance of 45 μm.
The spinal cord ventral horn was defined as the region of
gray matter on the ventral side of a horizontal line crossing
through the central canal, bounded by a vertical midline
through the sagittal plane. Images of the ventral horn were
captured at 400 × magnification and cells were counted
using ImageJ software (National Institutes of Health,
Bethesda, MD, USA) and Adobe CS6 (Adobe Systems In-
corporated, San Jose, CA, USA). Counts from the right and
left ventral horns of each section were averaged and di-
vided by the area in square millimeters. To avoid pseudore-
plication, the average count from three sections was used
as a single measurement per animal for statistical analysis.
At each time point, SOD1G93A and WT animals were com-
pared using an independent samples t-test (SPSS Statistics
20, IBM Corp., Armonk, NY, USA). A Welch t-test correc-
tion was applied if Levene’s test showed that the variance
in WTand SOD1G93A measurements was substantially dif-
ferent. Data are presented as mean ± standard error of the
mean, and the statistical test used for the comparison is
indicated (t-test = independent samples t-test for equal
variances; Welch t-test = independent samples t-test for
unequal variances), with P < 0.05 considered significant.
Semi-quantitative analysis of the expression level of
Arg1 and iNOS in SOD1G93A microglia was performed
in a subset of microglia. For both Arg1 and iNOS, one
section was randomly selected from each animal at
6 weeks of age (n = 3) and at 22 weeks of age (n = 4).The cell bodies of eight microglia, showing the strongest
Arg1 or iNOS staining in these sections, were outlined
in ImageJ. The percentage of the cell body area showing
positive immunostaining for Arg1 or iNOS was then cal-
culated. To account for any variation in immunostaining
intensity and background fluorescence between sections,
positive immunostaining in 8-bit black and white images
was defined as any pixels having a gray value greater
than 3.5 standard deviations above the mean gray value
of the whole image.
Immunolabeling for ubiquitin in paraffin-embedded
SOD1G93A and wild-type spinal cord tissue
To determine the age at which neuronal pathology in the
SOD1G93A mice became evident, we immunostained for
ubiquitin in paraffin-embedded lumbar spinal cords (6,
10, 14 and 25 weeks of age), and cervical spinal cords (10,
14, 18 and 22 weeks of age). Dephosphorylated neurofila-
ment (SMI32) was used as a motor neuron marker to
examine the localization of ubiquitin pathology. Anti-
ubiquitin and SMI32 were applied overnight and detected
with anti-rabbit-AlexaFluor594 and anti-mouse-Alexa
Fluor488 (Table 1). Immunostaining was examined using
a fluorescence microscope (Leica DM LB2) and images
were acquired on a Clara CCD cooled camera (Andor
Technology, Belfast, UK) using NIS-Elements D software
(Nikon, Tokyo, Japan).
Assessment of functional and behavioral changes in
SOD1G93A and wild-type mice
Functional assessment of mice
Seventeen SOD1G93A and 13 WT female mice were
assessed from pre-symptomatic stages through to 25 weeks
(disease endpoint). Body weight was measured at least
every 3 days, and daily when the mice were nearing dis-
ease endpoint. The wire-hang test, used to assess the abil-
ity to hang on to a wire cage lid when inverted (up to a
maximum of 60 seconds), was measured once per week
and the longest hang duration of three attempts was re-
corded. Stride pattern was examined once per week, with
front (red) and rear (blue) nontoxic paint (GlobalColours,
Marrickville, Australia) paw prints recorded as the mice
walked along a 60 cm length of paper. Parameters mea-
sured from the stride pattern were stride length (distance
between consecutive rear paw prints on the same side),
hind-base width (lateral distance between hind paws),
front-base width (lateral distance between front paws) and
uniformity measurement (difference in placement of the
hind paw compared with that of the front paw from the
previous step) [24].
Statistical analysis of functional data
Body weight and stride test measurements were averaged
so each mouse had one measurement per week. WT and
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U test (MWU) for nonparametric data (SPSS Statistics
20). All data are presented as mean ± standard error of the
mean, with P < 0.05 considered significant.
Results
SOD1G93A mice show an increasing number of microglial
cells in the lumbar ventral horn as disease progresses
Both Iba1 and TL labeling showed an increase in the
number of microglial cells in the ventral horn of the lum-
bar spinal cord, at the symptomatic and end-stages
of disease in SOD1G93A mice (Figure 1; arrows in
Figure 1A-D indicate microglia labeled with Iba1). Iba1Figure 1 Anti-ionized calcium binding adaptor molecule 1 (Iba1) and to
human superoxide dismutase transgene (SOD1G93A) and wild-type (WT)
in A-D) were present in the ventral horn at 6 weeks of age in WT (A) and SOD
of age in WT mice (C), but was substantially increased at 25 weeks (disease en
tomato lectin (F) increased with disease progression. Scale bar 50 μm in A-D.immunolabeling revealed an increased number of
microglia in the lumbar ventral horn of SOD1G93A mice
compared to WT mice at 18 weeks of age (178 ± 7 micro-
glia/mm2 versus 85 ± 26 microglia/mm2, t-test P = 0.025),
with the number of microglia in SOD1G93A mice continu-
ing to increase until disease endpoint (Figure 1E). More in-
tense labeling was observed in microglia with TL than with
Iba1. Given this increased sensitivity, the number of TL-
labeled microglia in SOD1G93A mice (208 ± 9 microglia/
mm2) was greater than that of WT mice (169 ± 8
microglia/mm2, t-test P = 0.034) beginning at 14 weeks
of age and thereafter (Figure 1F). Thus, by both mea-
sures of microglial number, Iba1-immunolabeling andmato lectin labeling in amyotrophic lateral sclerosis-linked mutant
lumbar spinal cord ventral horn. Few Iba1-positive microglia (arrows
1G93A (B) mice. The number of microglia was not increased at 25 weeks
dpoint, EP) in SOD1G93A mice (D). Microglial labeling with Iba1 (E) and
*P < 0.05, **P < 0.01, ***P < 0.001. NY, Nuclear yellow.
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of microglia in SOD1G93A spinal cords from 14 weeks
of age onwards.
SOD1G93A mice show an increasing number of arginase1-
positive microglia in the lumbar ventral horn as disease
progresses
Immunoreactivity for Arg1 was present in a subset of
microglial cells within the lumbar ventral horn in both
SOD1G93A and WT mice (Figure 2A-D, arrows). In WT
mice, the numbers of Arg1-positive and Arg1-negativeFigure 2 Arginase1 (Arg1) expression in microglia of amyotrophic later
(SOD1G93A) and wild-type (WT) lumbar spinal cord ventral horn. A subse
Arg1 (green) (arrows, A-D) at 10 weeks of age in both WT (A) and SOD1G93A (
22 weeks of age in WT mice (C); in contrast, 22-week SOD1G93A spinal cord (D
of Arg1-negative and Arg1-positive microglia remained constant over time in
disease progression in SOD1G93A mice (F). Scale bar 50 μm in A-D. *P < 0.05, *microglia remained relatively constant over time
(Figure 2E), with more Arg1-negative than Arg1-positive
microglia at all time points (Welch t-test P = 0.079 at
6 weeks; t-test P < 0.05 at 10 to 25 weeks). In SOD1G93A
mice the number of Arg1-negative microglia increased
slightly over time (Figure 2F). At 6 and 10 weeks of age,
the SOD1G93A lumbar ventral horn showed more Arg1-
negative than Arg1-positive microglia, a pattern similar to
that found in the WT ventral horn. However, the number
of Arg1-positive microglia in SOD1G93A mice increased
progressively from 14 weeks of age (86 ± 12 microglia/al sclerosis-linked mutant human superoxide dismutase transgene
t of ventral horn tomato lectin (TL)-positive (red) microglia expressed
B) mice. The number of microglia expressing Arg1 was unchanged at
) showed a far greater number of Arg1-positive microglia. The numbers
WT mice (E). The number of Arg1-positive microglia increased with
*P < 0.01, ***P < 0.001. NY, Nuclear yellow; EP, endpoint
Figure 3 (See legend on next page.)
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Figure 3 Inducible nitric oxide synthase expression in microglia of amyotrophic lateral sclerosis-linked mutant human superoxide dismutase
transgene (SOD1G93A) and wild-type (WT) lumbar spinal cord ventral horn. The majority of tomato lectin (TL)-positive microglia (red) in the ventral
horn did not express inducible nitric oxide synthase (iNOS) (arrows, A,B) at 6 weeks of age in either WT (A) or SOD1G93A (B) mice. A subset of microglia
were iNOS-positive (green) (arrows, C,D). The numbers of iNOS-positive and iNOS-negative microglia stayed relatively constant over time in WT mice (E).
The number of iNOS-positive microglia increased with disease progression in SOD1G93A mice; the number of iNOS-negative microglia increased at 22
and 25 weeks of age in SOD1G93A mice (F). The combined data from Figure 2F and 3F show that the number of both arginase1 (Arg1)-positive and
iNOS-positive microglia increased with disease progression (G); the percentage of microglia expressing Arg1 and expressing iNOS also increased with
time (H). Scale bar 50 μm in A-D. *P< 0.05, **P< 0.01, ***P< 0.001. NY, Nuclear yellow; EP, endpoint.
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25 weeks, the number of Arg1-positive microglia was
greater than the number of Arg1-negative microglia in the
SOD1G93A lumbar ventral horn (22 weeks: 286 ± 29 Arg1-
positive microglia/mm2 versus 157 ± 22 Arg1-negative
microglia/mm2, t-test P = 0.006; 25 weeks: 377 ± 24 Arg1-
positive microglia/mm2 versus 180 ± 27 Arg1-negative
microglia/mm2, t-test P = 0.005) (Figure 2F). At endpoint,
there was an 18-fold increase in Arg1-positive microglia
when compared to 10 weeks of age (Figure 2F).
SOD1G93A mice show an increasing number of inducible
nitric oxide synthase-expressing microglia in the lumbar
ventral horn as disease progresses
Within the lumbar ventral horn, both microglial cells lack-
ing iNOS (Figure 3A,B, arrows) and expressing iNOS (Fig-
ure 3C,D, arrows) could be observed. In WT mice there
were more iNOS-negative than iNOS-positive microglia
at all time points (Welch t-test P = 0.126 at 6 weeks; t-test
P < 0.05 at 10 to 25 weeks; Figure 3E) with iNOS-positive
microglia comprising less than 20% of total microglia. In
SOD1G93A mice the number of iNOS-expressing microglia
showed an increasing trend beginning at 14 weeks, al-
though the number of iNOS-positive microglia remained
less than the number of iNOS-negative microglia up to
22 weeks of age (t-test P < 0.05 at 6 to 22 weeks) due to a
concomitant increase in the number of iNOS-negative
microglia (Figure 3F). Only at 25 weeks of age (disease
endpoint) was there no difference between iNOS-positive
(100 ± 54 microglia/mm2) and iNOS-negative microglia
(281 ± 15 microglia/mm2, t test P = 0.069). By disease end-
point, the number of iNOS-expressing microglia had in-
creased approximately seven times from the 10-week old
SOD1G93A lumbar spinal cord. A direct comparison be-
tween the number of Arg1-positive and iNOS-positive
microglia in SOD1G93A lumbar ventral horn (Figure 3G;
data compiled from Figure 2F and Figure 3F) indicated
that the number of Arg1-positive microglia was consist-
ently greater than the number of iNOS-positive microglia
at 18 weeks of age (130 ± 15 Arg1-positive microglia/mm2
versus 72 ± 13 iNOS-positive microglia/mm2, t test P =
0.040), and this difference was maintained till disease end-
point (Figure 3G). When the cell counts were expressed in
terms of percentage of microglia expressing Arg1 or iNOS(Figure 3H), a similar trend was obtained. The percentage
of SOD1G93A lumbar microglia expressing Arg1 increased
over time, from 14% at 10 weeks of age to 65% at 22 weeks
of age. Over the same period, the percentage of SOD1G93A
lumbar microglia expressing iNOS increased from 8% to a
peak of 33% (Figure 3H).
SOD1G93A lumbar microglia show increasing arginase1
and inducible nitric oxide synthase immunoreactivity with
disease progression
Ventral horn microglia from randomly selected lumbar
spinal cord sections from SOD1G93A mice showed an in-
crease in the percentage area occupied by Arg1 and
iNOS immunoreactivity between 6 weeks and 22 weeks
of age (Figure 4). At 6 weeks of age, approximately 6%
of the microglial cell body area was occupied by Arg1
immunoreactivity, whereas less than 1% of the cell body
area contained iNOS immunoreactivity (Figure 4A,C,E).
At 22 weeks of age, Arg1 immunoreactivity occupied ap-
proximately 30% of the cell body area, and iNOS immu-
noreactivity occupied around 5% of the cell body area
(Figure 4B,D,E).
Arginase1 and inducible nitric oxide synthase-expressing
microglia in the cervical spinal cord of wild-type and
SOD1G93A mice
The current study focuses primarily on the histological
changes in the lumbar spinal cord of SOD1G93A mice, be-
cause motor weakness is first detectable in the hindlimbs
in this mouse model. However, given the later involve-
ment of the forelimbs [4,25] which are innervated by cer-
vical motor neurons, we have made a brief comparison of
microglial expression of putative inflammatory markers in
the cervical spinal cord of WT and SOD1G93A mice to de-
termine whether temporal differences in Arg1 or iNOS
expression between cervical and lumbar microglia may ex-
plain the differential involvement of the forelimbs and
hindlimbs. In the WT mice, similar to the lumbar spinal
cord, the numbers of Arg1-positive and Arg1-negative
cervical microglia remained relatively constant over time
(Figure 5A), with more Arg1-negative than Arg1-positive
microglia at 14 weeks and after (t-test P < 0.05). In the
SOD1G93A cervical ventral horn, the number of Arg1-
positive microglia was comparable to the number of Arg1-
Figure 4 Percentage area occupied by arginase1 (Arg1) and inducible nitric oxide synthase (iNOS) immunoreactivity in amyotrophic
lateral sclerosis-linked mutant human superoxide dismutase transgene (SOD1G93A) lumbar spinal cord microglia. The percentage area of
the microglial cell body occupied by Arg1 (A,B) or iNOS (C,D) positive immunoreactivity was examined at 6 weeks (A,C) and 22 weeks (B,D) of
age in a subset of microglia displaying the strongest immunoreactivity. The percentage of cell body area occupied by Arg1 was higher at
22 weeks of age than at 6 weeks of age; the percentage of cell body area occupied by iNOS was also higher at 22 weeks of age than at 6 weeks
of age (E). Scale bar 10 μm in A-D. ***P < 0.01. TL, tomato lectin; NY, Nuclear yellow.
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Figure 5 Expression of arginase1 (Arg1) and inducible nitric oxide synthase (iNOS) in microglia of the ventral horn of wild-type (WT)
and amyotrophic lateral sclerosis-linked mutant human superoxide dismutase transgene (SOD1G93A) cervical spinal cord. The number of
Arg1-negative and Arg1-positive cervical microglia remained relatively constant over time in WT mice (A). In the cervical spinal cord of SOD1G93A
mice, the number of Arg1-positive and Arg1-negative microglia remained equivalent until 22 weeks of age, when there was an increase in the
number of Arg1-positive microglia (B). There were greater numbers of iNOS-negative microglia than iNOS-positive microglia throughout the time
course in WT mice (C). The numbers of iNOS-positive microglia and iNOS-negative microglia both increased with disease progression in the
SOD1G93A cervical spinal cord (D). *P < 0.05, **P < 0.01, ***P < 0.001.
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in the number of Arg-positive microglia was recorded
(265 ± 39 Arg1-positive microglia/mm2 versus 71 ± 22
Arg1-negative microglia/mm2, t-test P = 0.012; Figure 5B).
The percentage of Arg1-positive microglia in the SOD1G93A
cervical ventral horn increased from 45% at 10 weeks of
age to 79% at 22 weeks of age. Therefore, similar to the
SOD1G93A lumbar spinal cord, the cervical region also
showed a trend of increasing numbers of Arg1-expressing
microglia at 22 weeks of age.
With regard to iNOS labeling, the cervical spinal cord
of WT mice showed a constant population of microglia,
with more iNOS-negative than iNOS-positive microglia
(Welch t-test P = 0.049 at 10 weeks; t-test P < 0.05 at 14 to
22 weeks; Figure 5C). In the cervical spinal cord of
SOD1G93A mice, the number of iNOS-positive microglia
increased over time from 10 weeks of age (11 ± 7 iNOS-
positive microglia/mm2) to 22 weeks of age (68 ± 3 iNOS-
positive microglia/mm2) (Figure 5D). The number of
iNOS-negative microglia also increased over the sametime period (80 ± 13 iNOS-negative microglia/mm2 at
10 weeks versus 272 ± 57 iNOS-negative microglia/mm2
at 22 weeks of age) (Figure 5D). However, due to the use
of the Welch t-test correction for unequal variances, there
were no significant differences detected between iNOS-
positive and iNOS-negative microglial numbers in the
SOD1G93A cervical spinal cord (Welch t-test P = 0.051 to
0.076 at 10 to 22 weeks). The percentage of iNOS-positive
microglia in the SOD1G93A cervical spinal cord increased
from 11% at 10 weeks of age to 24% at 18 weeks of age,
and 20% at 22 weeks of age.
SOD1G93A mice show a decreasing number of arginase1-
negative motor neurons in the lumbar ventral horn as
disease progresses
In both SOD1G93A and WT mice a number of motor neu-
rons in the ventral horn of the lumbar spinal cord
expressed Arg1 (Figure 6). The number of Arg1-positive
motor neurons was not different between WT and
SOD1G93A mice at any time point measured (Figure 6C,
Figure 6 Arginase1 (Arg1) expression in motor neurons of wild-type (WT) and amyotrophic lateral sclerosis-linked mutant human
superoxide dismutase transgene (SOD1G93A) ventral horn. Arg1 immunostaining was observed in a punctate pattern in motor neuron cell bodies
(A, inset). At 22 weeks of age, Arg1 labeling was far more prominent in WT motor neurons (A) than in SOD1G93A motor neurons (B). The majority of
Arg1-positive cells in the 22-week SOD1G93A spinal cord were microglial cells (B; white box in inset). At 25 weeks of age, WT mice showed fewer
Arg1-negative than Arg1-positive motor neurons (C). In SOD1G93A mice, there was an earlier decline in the number of Arg1-negative motor neurons,
from approximately 18 weeks of age (D), with significantly fewer Arg1-negative than Arg1-positive motor neurons at 18, 22 and 25 weeks of age
(disease endpoint, EP). Scale bar 300 μm in A and B, 130 μm in A (inset), 125 μm in B (inset). *P < 0.05, **P < 0.01, ***P < 0.001.
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rons stayed relatively constant from 6 to 22 weeks, but
was decreased at 25 weeks (19 ± 8 Arg1-negative motor
neurons/mm2), such that it was less than the number of
Arg1-expressing motor neurons (94 ± 18 Arg1-positive
motor neurons/mm2, t-test P = 0.018; Figure 6C). In com-
parison, the number of Arg1-negative motor neurons de-
clined progressively in SOD1G93A mice from 6 weeks of
age (98 ± 13 Arg1-negative motor neurons/mm2) to
25 weeks of age (1 ± 1 Arg1-negative motor neurons/
mm2) (Figure 6D). A difference between the number of
Arg1-negative and Arg1-positive motor neurons in the
SOD1G93A lumbar spinal cord was first detected at
18 weeks of age (21 ± 14 Arg1-negative motor neurons/
mm2 versus 78 ± 15 Arg1-positive motor neurons/mm2, t
test P = 0.048), and the number of Arg1-negative motor
neurons declined further until disease endpoint (Figure 6D).
Ubiquitin pathology is present in SOD1G93A lumbar spinal
cord from 6 weeks of age
Diffuse ubiquitin immunolabeling was present in the
nucleus of both WT (Figure 7A,C,E) and SOD1G93A
(Figure 7B,D,F) lumbar motor neurons at 6, 10, 14 and
25 weeks of age (Figure 7). Ubiquitin-positive inclu-
sions were present in the cytoplasm of SOD1G93A
motor neurons from as early as 6 weeks of age (Figure 7B,
arrow). The number of ubiquitinated inclusions in thespinal cord increased with disease progression, with some
non-neuronal ubiquitin immunoreactivity evident from
10 weeks of age (Figure 7D). By disease endpoint, numer-
ous large ubiquitin-positive inclusions were located out-
side SMI32-positive motor neuron cell bodies in the gray
matter (Figure 7F), and were also present in the white
matter. These inclusions may be present in neuritic pro-
cesses, glial cells or within the remnants of degenerating
motor neurons. Additionally, immunolabeling for dephos-
phorylated neurofilaments (SMI32) revealed the presence
of vacuolated lumbar motor neurons from 10 weeks of age
in SOD1G93A mice (Figure 7D, arrow). No such ubiquitin
pathology or vacuolation was observed in WT motor neu-
rons (Figure 7A,C,E).
In the SOD1G93A cervical spinal cord, immunostained
for ubiquitin at 10, 14 and 22 weeks of age (Figure 7G-I),
cytoplasmic ubiquitin-positive inclusions were present in
motor neurons from 10 weeks of age (Figure 7G, arrow),
with non-neuronal ubiquitin aggregates distributed
sparsely if present. At 14 weeks of age, ubiquitinated
aggregates were observed in both soma of cervical
motor neurons and within the neuronal processes of
the neuropil (Figure 7H, arrow) or as an extracellular
aggregate (Figure 7H, arrowhead). Ubiquitin pathology in-
creased with disease progression in the cervical spinal cord
as in the lumbar spinal cord; by 22 weeks of age, multiple
non-neuronal ubiquitinated aggregates were present in the
Figure 7 Ubiquitin immunolabeling in amyotrophic lateral sclerosis-linked mutant human superoxide dismutase transgene (SOD1G93A) and
wild-type (WT) mice. Ubiquitin (red, A-F) was localized to the nucleus in WT (A,C,E) and SOD1G93A (B,D,F) motor neurons (SMI32, green, A-F). In
SOD1G93A mice lumbar spinal cord, intracellular ubiquitin-positive inclusions were present from 6 weeks of age (arrow, B) onwards. SOD1G93A mice also
showed extra-neuronal ubiquitin-positive inclusions from 10 weeks of age (D), with numerous ubiquitin aggregates by 25 weeks of age (F). Additionally,
vacuolated lumbar motor neurons were observed from 10 weeks of age (arrow, D). Intracellular ubiquitinated aggregates were observed at 10 weeks of
age in cervical motor neurons (G, arrow); at 14 weeks of age, intracellular (H, arrow) and extracellular (H, arrowhead) ubiquitin-positive aggregates were
present in the SOD1G93A cervical ventral horn, and increased in number with time (I, 22 weeks of age). Scale bar 12 μm in A-F, 20 μm in G-I.
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pathology appears to be slightly delayed in the cervical
spinal cord compared to the lumbar spinal cord of
SOD1G93A mice.
As disease progresses, SOD1G93A mice differ from wild-type
mice in body weight, outcome of wire-hang test, stride
length and uniformity measurement
Survival
Average survival time of the SOD1G93A mice was 164 ± 2 days
and median survival (50%) was 166 ± 2 days. All SOD1G93A
mice reached disease endpoint as determined by weight loss
(a loss of 20% from their maximum body weight) before los-
ing their righting reflex. All WT mice remained healthy at
the endpoint ages of their SOD1G93A littermates.Body weight
Body weight rose continuously for WT mice throughout
the duration of the study. In contrast, the SOD1G93A
mice displayed a curved body weight trajectory, achiev-
ing maximal weight (20.3 ± 0.2 g) at 16 weeks of age
(Figure 8A). The average body weight of SOD1G93A mice
was lower than that of WT mice from the age of
14 weeks (20.0 ± 0.2 g and 21.0 ± 0.5 g respectively,
MWU P = 0.035) onwards, with the body weight differ-
ence increasing with disease progression.
Wire-hang test
WT mice were able to maintain wire hang duration time
on inverted wire bars for 60 seconds (the set maximum
time) throughout the course of the study, while SOD1G93A
Figure 8 Functional measures of disease progression in wild-type (WT) and amyotrophic lateral sclerosis-linked mutant human superoxide
dismutase transgene (SOD1G93A) mice. Body weight increased continuously in WT mice but followed a curved trajectory in SOD1G93A mice,
becoming significantly less than that of WT mice at 14 weeks of age and reaching peak body weight at approximately 16 weeks of age (A). WT mice
were able to maintain wire hang duration throughout the study, while SOD1G93A mice became unable to maintain a 60-second hang duration from
15 weeks of age onwards (B). SOD1G93A mice displayed a lower stride length (C) and a higher uniformity measure (D) than WT mice at 18 weeks and
thereafter. Front-base width (E) and hind-base width (F) showed no consistent changes between WT and SOD1G93A mice over time. *P < 0.05,
P < 0.01, #P < 0.001.
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until 14 weeks of age (Figure 8B). At 15 weeks,
SOD1G93A mice recorded lower wire-hang times than
WT mice (42 ± 5 seconds and 58 ± 2 seconds, respect-
ively, MWU P = 0.012), and by 20 weeks SOD1G93A
mice could only achieve a wire-hang time of less than
10 seconds (Figure 8B). As an interesting aside, we
noted that the first 3 to 4 weeks of testing were highly
variable for both SOD1G93A and WT mice. We attri-
bute these variable measurements to a learning effect
for these mice, whose home cages had a plastic lid - the
only wire structure in the home cage was the foodhopper, hence these mice had no prior experience
clinging onto a set of wire bars while inverted.Stride length
The average stride length of WT mice stayed relatively con-
stant over time, while the stride length of SOD1G93A mice
declined from approximately 17 weeks of age (Figure 8C).
The stride length of SOD1G93A mice was less than that of
WT littermates at 18 weeks (5.2 ± 0.2 cm and 5.9 ± 0.2 cm,
respectively, MWU P = 0.021), with the difference between
the two groups increasing progressively over time thereafter.
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Uniformity measurement, the distance between placement
of the hind paw compared with the front paw from the
previous step, differed between WT and SOD1G93A mice
over time (Figure 8D). WT mice maintained a uniformity
distance of less than 0.5 cm throughout the study; that is,
hind paw placement was within 0.5 cm of the front paw
placement on the previous step. However, this began to
differ between genotypes at 18 weeks of age, with
SOD1G93A mice showing a larger uniformity measurement
(SOD1G93A 0.7 ± 0.1 cm versus WT 0.3 ± 0.1 cm, MWU
P = 0.002). The difference between the two groups was
maintained from 18 weeks to 24 weeks of age (Figure 8D);
the single uniformity value obtained from the one surviv-
ing SOD1G93A mouse at the 25-week time point was in-
sufficient to perform statistical analysis. The increase in
uniformity in SOD1G93A mice likely reflects the dimin-
ished strength of the hindlimb with disease progression,
and resultant inability to move the hindlimb forward effi-
ciently during walking.
Front-base width and hind-base width
Front-base width did not differ between WT and
SOD1G93A mice, apart from the isolated time points at 17
and 24 weeks (Figure 8E). Similarly, for most time points,
WT and SOD1G93A mice showed similar values of hind-
base width (Figure 8F). SOD1G93A mice showed a slight
decline in hind-base width over time from 21 weeks on-
wards; however this was still within the range of measure-
ments obtained at earlier time points (Figure 8F).
Discussion
ALS is a neurodegenerative disease affecting the motor
system, with disease progression thought to be influenced
by inflammatory responses in the spinal cord. A main
finding of this study was that the total number of micro-
glia in the ventral horn of the SOD1G93A lumbar spinal
cord, from 14 weeks of age, was mainly associated with an
increase in Arg1-positive microglia (Figures 1 and 2). In-
creasing numbers of iNOS-expressing microglia were also
demonstrated in the ventral horn (Figure 3), while the
number of motor neurons lacking Arg1 declined
sharply from 18 weeks of age in the SOD1G93A spinal
cord (Figure 6). A similar trend of increasing Arg- and
iNOS-expressing microglia over time appeared to be
present in the SOD1G93A cervical spinal cord (Figure 5).
Additionally, we found that ubiquitin pathology was de-
tected in the lumbar spinal cords of 6-week old
SOD1G93A mice (Figure 7), before any observable func-
tional decline (Figure 8).
Microgliosis in the SOD1G93A spinal cord
Our results demonstrated a substantial increase in the
number of microglial cells in the SOD1G93A mouselumbar spinal cord, starting from symptom onset at
14 weeks, and increasing with disease progression through
to endpoint (Figure 1). This result is consistent with previ-
ous reports in the literature, describing an increase in the
number of activated microglia in spinal cord gray matter
at disease onset, and increasing throughout disease pro-
gression [11,12,18,26-28]. A few previous reports have also
demonstrated an increase in the number of microglia dur-
ing the pre-symptomatic stage in SOD1G93A mice [10],
SOD1G93A rats [29] and SOD1H46R rats [30]. These studies
may show earlier increases in microglia due to the use of
CD11b [10,29], perhaps a more sensitive marker of micro-
glia than the TL used in the present study. Additionally, it
is possible that the SOD1H46R rat model may exhibit a
slightly different disease course with altered timing of
microglial activation compared with the SOD1G93A rodent
models, as differences in the survival time and disease se-
verity between SOD1G93A and SOD1H46R mouse models
have been previously reported [31]. Alternatively, the pre-
symptomatic microglial activation seen in previous studies
may be a response to factors released by dysfunctional
motor neurons before the onset of overt functional defi-
cits. Given that in this study we saw the presence of intra-
cellular ubiquitinated aggregates as early as 6 weeks of age
in the lumbar spinal cord, while microgliosis was observed
from 14 weeks of age, the data indicate that the initial
microgliosis might be a reactive response to the presence
of motor neuron dysfunction and degeneration in the
lumbar spinal cord. Multiple lines of evidence indicate
that microglial activation plays a key role in the progres-
sion of disease after onset [12,32,33], and indeed we ob-
served that obvious changes in functional ability of the
SOD1G93A mice, such as the alterations to stride pattern
parameters, occurred at 18 weeks of age - 4 weeks after
the initial increase in the number of microglia in the lum-
bar spinal cord. Thus, the increase in microglial numbers
preceded the transition into a phase of disease progression
in which functional ability declined rapidly.
Phenotype of microglia in the SOD1G93A spinal cord
We found a seven-fold increase in the number of iNOS-
positive microglia between the pre-symptomatic stage and
disease endpoint, which translated to an increase in the
percentage of microglia expressing iNOS from less than
10% pre-symptomatically to over 30% at 22 weeks of age
(Figure 3). Interestingly, the number of lumbar spinal cord
microglia expressing Arg1 also increased at disease onset
and continued to increase throughout disease progression,
with an 18-fold increase at endpoint in comparison to
pre-symptomatic levels; similarly, the percentage of micro-
glia expressing Arg1 increased from below 20% in pre-
symptomatic lumbar spinal cord to over 60% at endpoint
(Figures 2 and 3). The increasing numbers of iNOS-
expressing and Arg1-expressing microglia in the
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given that both Arg1 and iNOS have competitive roles in
L-arginine metabolism. The increase in the number of
Arg1-expressing lumbar microglia as disease progresses
may be an attempt to limit tissue damage and neuronal
degeneration caused by disease processes [20,34], but
these results did not appear to be in line with the widely-
perceived switch from an M2 to an M1 phenotype in
SOD1G93A mice [12,13].
To examine whether the expression levels of Arg1 or
iNOS within individual microglia were altered during dis-
ease progression, a semi-quantitative analysis of protein ex-
pression level was carried out using sections
immunostained for Arg1 and for iNOS (Figure 4). This
analysis showed that, in Arg1-positive microglia, the
amount of Arg1 immunoreactivity increased with disease
progression; the same was true for iNOS-positive microglia
showing an increase in iNOS immunoreactivity (Figure 4).
The percentage area occupied by Arg1 immunoreactivity
increased approximately five-fold between 6 and 22 weeks
of age, yet the percentage area occupied by iNOS immuno-
reactivity increased approximately 25-fold between 6 and
22 weeks of age due to the small amount expressed at
6 weeks of age (Figure 4). Conversely, while the absolute
levels of Arg1 and iNOS protein cannot be reliably com-
pared by immunohistochemistry intensity due to different
antibody-antigen binding strengths, the percentage area
occupied by Arg1 does appear to be larger than that occu-
pied by iNOS. Thus, our results show evidence of both
neurotoxic and neuroprotective processes in SOD1G93A
spinal cord microglia, as implicated by increasing immuno-
reactivity for iNOS and Arg1, respectively, over time.
Previous studies have reported the upregulation of M2
microglial markers such as Ym1 and MCP-1 in
SOD1G93A mouse spinal cord during the early, slow-
progressing phase of disease [12,32]. Subsequently dur-
ing the rapidly-progressing disease phase, M2 markers
were downregulated and the M1 markers tumor necrosis
factor α, NOX2 and IL-6 became more prominent
[12,13,18,32,35,36]. While the increase in iNOS immu-
noreactivity in SOD1G93A microglia with disease pro-
gression in this study would agree with the upregulation
of M1 markers, we saw no concomitant decrease in ex-
pression of the M2 marker Arg1. The differences be-
tween our study and previous studies may be due to the
use of different techniques to assess microglial markers;
the current study used immunohistochemistry to reveal
cell-specific localization data, compared with mRNA or
protein data from homogenized spinal cord. Although
microglia are very likely to be the primary cell type re-
sponsible for cytokine production within the spinal cord,
other cell types including astrocytes and motor neurons
may also produce cytokines or inflammatory markers
which may skew the results of mRNA studies. Indeed, inthe current study, we observed that spinal cord motor neu-
rons expressed the putative M2 marker Arg1 (Figure 5).
Furthermore, it has been shown that certain M2 markers
such as Ym1 increased in endstage SOD1G93A mice [37].
Additionally, Chiu and colleagues demonstrated that
SOD1G93A microglia can show M2 characteristics, such as
increased production of insulin-like growth factor 1 and
decreased IL-6 expression, regardless of disease progres-
sion stage [26].
The use of mRNA from homogenized spinal cord
alone may limit interpretation of which proteins are spe-
cifically present in microglial cells. On the other hand,
the use of protein markers alone in this study resulted in
a different issue: we were unable to perform reliable
double-labeling for Arg1 and iNOS together due to per-
sistent antibody cross-reactivity. Thus, some microglia
expressing Arg1 may also have expressed iNOS. Add-
itionally, microglial phenotype is regulated by a number
of pro- and anti-inflammatory cytokines, some of which
(interferon γ, IL-4 and IL-10 [34]) have a direct effect on
Arg1 and iNOS activity [38], so it is conceivable that up-
regulation of Arg1 and iNOS in subsets of microglia
could occur as a response to the cytokines in the exter-
nal milieu of the microglia. Alternatively, the regulation
of iNOS and Arg1 levels may occur independently of the
classical M1/M2 phenotypes driven by changes in cyto-
kine production.
Comparison of arginase1 and inducible nitric oxide
synthase protein expression in the SOD1G93A lumbar and
cervical spinal cord
We compared the cervical and lumbar regions of the
spinal cord and investigated whether changes in Arg1 or
iNOS expression could explain the delayed involvement
of the forelimbs in the SOD1G93A mouse model. In the
SOD1G93A cervical ventral horn, the number of Arg1-
positive microglia was increased at 22 weeks of age,
while the number of iNOS-positive microglia also in-
creased slightly over time (Figure 5). Although these
trends were similar to those seen in the lumbar spinal
cord (Figures 2 and 3), a few small differences may indi-
cate a slightly different microglial environment in the
cervical spinal cord. First, at 10 weeks of age there were
equivalent numbers of Arg1-positive and Arg1-negative
microglia in the cervical spinal cord compared with a
predominance of Arg1-negative microglia (86%) in the
lumbar spinal cord, possibly indicating the existence of a
less inflammatory microenvironment in the cervical
spinal cord. Second, the percentage of microglia express-
ing Arg1 reached 79% at 22 weeks of age in the cervical
spinal cord, compared with 64% in the lumbar spinal
cord. Furthermore at 22 weeks, the percentage of micro-
glia expressing iNOS was 24% in the cervical spinal cord,
compared with 32% in the lumbar spinal cord. Taken
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tective microglial phenotype is present in the cervical
than the lumbar spinal cord during the time course of
the disease. It is difficult to elucidate from this study
whether the apparently less inflammatory microglial en-
vironment in the cervical spinal cord is due to delayed
neuronal degeneration, or vice versa. However, in line
with a previous study comparing cervical and lumbar
spinal cord regions, our results indicate that the cervical
spinal cord showed increased early production of an M2
marker compared to lumbar spinal cord in the
SOD1G93A mouse model [12].
Arginase1 protein expression in motor neurons
We examined the change in Arg1-negative and Arg1-
positive motor neurons over time in the SOD1G93A lumbar
spinal cord. The number of Arg1-negative motor neurons
decreased substantially after disease onset in SOD1G93A
mice, whereas the number of Arg1-positive motor neurons
remained relatively constant (Figure 6). Motor neurons
lacking Arg1 may be more vulnerable compared with
motor neurons which express Arg1, possibly due to NO
toxicity. Motor neurons in SOD1G93A mice are reported to
have decreasing Arg1 expression [19] and increasing iNOS
expression [39] with disease progression and can be pro-
tected by L-arginine supplementation [19]. The decreasing
level of Arg1 and increasing level of iNOS may disrupt the
normal balance of arginine metabolism, with SOD1G93A
motor neurons skewed towards iNOS-mediated produc-
tion of NO rather than Arg1-mediated production of orni-
thine [40-44]. Increased production of NO, mediated by
Arg1 inhibition, is toxic to motor neurons in vitro [45-47].
In addition to raising NO levels, low levels of Arg1 could
also decrease production of neuroprotective polyamines
such as spermine and spermidine, normally produced from
ornithine [19,48]. Thus, SOD1G93A motor neurons with
low levels of Arg1 may be more susceptible to toxicity due
to their higher levels of NO and lower levels of neuropro-
tective polyamines.
Functional decline and ubiquitin pathology
The current study confirmed the decline in function
over time in SOD1G93A mice, which has been well docu-
mented previously [4]. Our SOD1G93A cohort showed
divergence from their WT littermates in body weight
and in wire hang duration ability from 14 and 15 weeks
of age, respectively, with overt changes in stride parame-
ters becoming apparent at 18 weeks of age (Figure 8).
We therefore considered 14 weeks of age to be the point
of disease onset, for comparison with spinal cord
changes observed by immunohistochemistry. Our esti-
mate of 14 weeks of age is conservative compared to
previous studies in the SOD1G93A mouse on a C57BL/6
background, showing initial onset of disease symptomsdetectable at 11 weeks of age by observations of tremors
[12,32]. However, the development of overt stride par-
ameter differences at 18 weeks of age in the current
study correlates well with the transition into a rapidly
progressing phase of disease at approximately 18 weeks
of age, as measured using the BASH scoring system [32].
Additionally, in this study, we have shown that ubiqui-
tin pathology and vacuolated motor neurons were
present in the lumbar spinal cord of SOD1G93A mice at
6 weeks and 10 weeks of age, respectively (Figure 7).
The presence of vacuolated motor neurons and ubi-
quitinated aggregates in pre-symptomatic SOD1G93A
mice has been reported previously [49,50]. Compared
with our detection of disease onset at 14 weeks of
age (Figure 8), the presence of ubiquitin and neurofil-
ament pathology in SOD1G93A lumbar motor neurons
from 6 weeks of age onwards reinforces the idea that
pathological changes in the motor neuron cell body
occur well before onset of functional deficits, due to
the compensatory peripheral plasticity [51]. The later
appearance of pathological changes in the cervical
spinal cord correlate with the reported later involve-
ment of the forelimbs compared with the hindlimbs
in the SOD1G93A mice [25]. Unfortunately, in this
study we were not able to directly correlate delayed
cervical pathology with functional deficits, as our
measures of stride length, uniformity and wire hang
duration are all related to hindlimb function.
Conclusions
In summary, we have shown that the numbers of micro-
glia expressing the M2 marker Arg1, as well as the num-
bers of microglia expressing the M1 marker iNOS,
increase in the spinal cord during disease progression in
the SOD1G93A mouse model of ALS. It is likely that evalu-
ation of the cytokine protein profile will be key to under-
standing the overall neuroprotective or neurotoxic effects
of microglial activation on the spinal cord milieu. We have
also demonstrated a selective decrease in motor neurons
lacking expression of Arg1, and strategies to boost Arg1
expression may also be an appropriate therapeutic target
for treatment of human ALS. Modulation of microglial
immune responses remains an important target for ameli-
orating disease symptoms and the rate of disease progres-
sion in ALS.
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